Trial · NCT01849575
Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention
NCT01849575, Not applicable, Active not recruiting, Umeå University; results first posted 2020-05-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention. Trials, record NCT01849575. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01849575
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention
- NCT number
- NCT01849575
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 3,532 participants, actual
- Lead sponsor
- Umeå University
- Conditions
- Cardiovascular Diseases
- Interventions
- Intervention
- First posted
- 2013-05-08
- Last updated
- 2026-06-29
- Results first posted
- 2020-05-07
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | FRS | one year | Framingham risk score. Composite gender-specific algorithm used to estimate the 10-year cardiovascular risk of an individual, based on levels of blood pressure, total cholesterol, LDL-cholesterol, systolic blood pressure, treatment for high blood pressure, diabetes, smoking and age. Minimum value=0, maximum value 100. Higher score means a worse outcome, i.e. a higher risk of cardiovascular diseases. |
| Secondary | SCORE | Follow-up after one year | SCORE: European systematic coronary risk evaluation. Risk of death (%) in myocardial infarction within 10 years expressed as statistical assessment based on smoking, systolic blood-pressure, blood cholesterol, age and sex. SCORE is evaluated as a continuous variable with Minimum value=0%, maximum value=100%. Higher score means a worse outcome, i.e. a higher risk of cardiovascular diseases. |
| Secondary | Hospitalizations Due to Stroke, Myocardial Infarctions and Re-vascularizations | 10 years | Data will be collected from the In-patient registry at the National Board of Health and Welfare. |
| Secondary | Total Mortality and Cause-specific Mortality Due to Myocardial Infarctions and Stroke | 10 years | Data will be collected from the Causes of Deaths registry at the National Board of Health and Welfare. |
| Secondary | Total Mortality | 10 years | Data will be collected from computerized medical records from hospital care in the county, regional quality registry on myocardial infarctions and from the In-patient registry at the National Board of Health and Welfare. |
| Secondary | Carotid Atherosclerosis | 3 years after baseline | Carotid intima media thickness |
| Other | FRS, Adjusted for Baseline Values | Follow-up after three years during September 5 2016 - May 28 2019 | FRS=Framingham risk score. Composite gender-specific algorithm used to estimate the 10-year cardiovascular risk of an individual, based on levels of blood pressure, total cholesterol, LDL-cholesterol, systolic blood pressure, treatment for high blood pressure, diabetes, smoking and age. Minimum value=0, maximum value 100. Higher score means a worse outcome, i.e. a higher risk of cardiovascular diseases. |
| Other | SCORE Adjusted for Baseline Levels | Three years of follow-up, data collected during September 5 2016 - May 28 2019 | SCORE: European systematic coronary risk evaluation. Risk of death (%) in myocardial infarction within 10 years expressed as statistical assessment based on smoking, systolic blood-pressure, blood cholesterol, age and sex. SCORE is evaluated as a continuous variable with Minimum value=0%, maximum value=100%. Higher score means a worse outcome, i.e. a higher risk of cardiovascular diseases. |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | FRS | one year | % risk of a CVD event within 10 years | NUMBER | |
| SECONDARY | SCORE | Follow-up after one year | % risk of a CVD event within 10 years | NUMBER | |
| SECONDARY | Hospitalizations Due to Stroke, Myocardial Infarctions and Re-vascularizations | 10 years | |||
| SECONDARY | Total Mortality and Cause-specific Mortality Due to Myocardial Infarctions and Stroke | 10 years | |||
| SECONDARY | Total Mortality | 10 years | |||
| SECONDARY | Carotid Atherosclerosis | 3 years after baseline | All participants who completed the carotid ultrasound examination at the 3-year follow-up | mm | MEAN |
| OTHER_PRE_SPECIFIED | FRS, Adjusted for Baseline Values | Follow-up after three years during September 5 2016 - May 28 2019 | % risk of a CVD event within 10 years | NUMBER | |
| OTHER_PRE_SPECIFIED | SCORE Adjusted for Baseline Levels | Three years of follow-up, data collected during September 5 2016 - May 28 2019 | % risk of a CVD event within 10 years | NUMBER |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| FRS | Intervention | 12.2 | 99.5% Confidence Interval 11.6 to 12.9 | % risk of a CVD event within 10 years | |
| FRS | Control | 13.3 | 99.5% Confidence Interval 12.6 to 14.0 | % risk of a CVD event within 10 years | |
| SCORE | Intervention | 1.42 | 99.5% Confidence Interval 1.33 to 1.55 | % risk of a CVD event within 10 years | |
| SCORE | Control | 1.58 | 99.5% Confidence Interval 1.47 to 1.68 | % risk of a CVD event within 10 years | |
| Carotid Atherosclerosis | Intervention | 0.680 | Standard Deviation 0.151 | mm | |
| Carotid Atherosclerosis | Control | 0.685 | Standard Deviation 0.165 | mm | |
| FRS, Adjusted for Baseline Values | Intervention | 13.33 | 95% Confidence Interval 13.02 to 13.64 | % risk of a CVD event within 10 years | |
| FRS, Adjusted for Baseline Values | Control | 14.13 | 95% Confidence Interval 13.83 to 14.44 | % risk of a CVD event within 10 years | |
| SCORE Adjusted for Baseline Levels | Intervention | 1.69 | 95% Confidence Interval 1.64 to 1.74 | % risk of a CVD event within 10 years | |
| SCORE Adjusted for Baseline Levels | Control | 1.83 | 95% Confidence Interval 1.78 to 1.88 | % risk of a CVD event within 10 years |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intervention | 1,749 | |
| Overall Study | STARTED | Control | 1,783 | |
| Overall Study | COMPLETED | Intervention | 1,599 | |
| Overall Study | COMPLETED | Control | 1,576 | |
| Overall Study | NOT COMPLETED | Intervention | 150 | |
| Overall Study | NOT COMPLETED | Control | 207 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anxiety | Psychiatric disorders | Intervention | 50 | 1,749 | 50 |
| other | Anxiety | Psychiatric disorders | Control | 0 | 1,783 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intervention | 5 | 1,749 |
| Total, all-cause mortality | Control | 2 | 1,783 |
| Total, other adverse events | Intervention | 50 | 1,749 |
| Total, other adverse events | Control | 0 | 1,783 |
| Total, serious adverse events | Intervention | 0 | 1,749 |
| Total, serious adverse events | Control | 0 | 1,783 |
Source ClinicalTrials.gov
Papers28
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intervention vs Control: deaths from any cause | Trial comparisons |
| Intervention vs Control: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01849575
GET https://conductscience.org/api/trials/v1/NCT01849575/papers?page=2